Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time3' education - Mar. 17, 2017
ACC 2017 Dr. Paul Ridker discusses data of the SPIRE studies into use of the PCSK9 antibody bococizumab, including the unexpected attenuation of the LDL-c response over time in some patients, as a consequence of development of antibodies against the drug.
The SPIRE 1 and SPIRE 2 trials were presented during Late-Breaking Clinical Trial Session 1 (March 17), ACC 2017, Washington DC, USA
Recorded at ACC 2017, Washington DC, USA.
Dr. Paul M. Ridker (Co-chair Executive Committee, SPIRE clinical trials program and director for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston, MA, USA)